By Matt Grossman

Galapagos NV and Gilead Sciences Inc. said Wednesday that they have halted their Phase 3 trials studying the use of ziritaxestat, an autotaxin inhibitor, as a treatment for patients with idiopathic pulmonary fibrosis.

The decision is based on a recommendation from the trial's independent data-monitoring committee, the companies said. The committee concluded that the drug's benefit-risk profile did not support continuing the study.

The Phase 3 program consisted of two trials that aimed to enroll 1,500 patients combined. Patients were randomized to receive varying dose amounts of ziritaxestat or a placebo while they continued standard-of-care background treatment.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

February 10, 2021 09:25 ET (14:25 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Galapagos
Grafico Azioni Galapagos (EU:GLPG)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Galapagos